---
title: "Can-Fite (CANF.US) sees volatility, shares down intraday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284800271.md"
description: "Can-Fite BioPharma（CANF.US）现价 $2.940，当日 -1.67%，盘中 5 分钟涨幅曾超 3%，市值 0.04 亿。企业聚焦创新药物研发，近期临床 2a 期积极数据推动股价剧烈波动。此前合作方 Vetbiolix 完成骨关节炎项目入组，市场关注后续试验进展。"
datetime: "2026-04-30T15:20:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284800271.md)
  - [en](https://longbridge.com/en/news/284800271.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284800271.md)
---

# Can-Fite (CANF.US) sees volatility, shares down intraday

Can-Fite BioPharma (CANF.US) is trading at $2.940, down **\-1.67%** intraday, with a 5-minute spike previously above 3%. Market cap is 4 million.

The company specializes in novel drug research, with recent positive Phase 2a clinical results driving sharp price swings. Vetbiolix recently completed enrollment for a canine osteoarthritis study, and investors are watching upcoming trial updates.

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study](https://longbridge.com/en/news/287280796.md)
- [Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg Cohort](https://longbridge.com/en/news/287276070.md)
- [Patients on Lilly's next-gen obesity drug lost 28% of body weight, company says](https://longbridge.com/en/news/287203888.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Vertex Says Health Canada Accepts Suzetrigine Application for Review](https://longbridge.com/en/news/287257602.md)